Request for approval submitted by University of Minnesota professor.
The Food and Drug Administration (FDA) published a document last week that declined the emergency use authorization of the antidepressant fluvoxamine as a treatment for COVID-19. Though it was proposed that the drug could be useful for those with less severe symptoms and non-hospitalized COVID-19 patients, the FDA found the data to be “insufficient” in light of other scientific evidence.
The emergency use authorization request was submitted by University of Minnesota professor Dr. David Boulware, who was disappointed with the FDA’s assessment. He had hoped that the emergency authorization could help those with mild COVID-19 infections have access to a widely available generic drug and address their illness on their own.
As the Lord Leads, Pray with Us…
- For FDA researchers and scientists as they test and review medications for authorization.
- For Commissioner Califf to seek the Lord’s wisdom as he heads the FDA.
Sources: The Hill, Reuters
